Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/25415

Title:	Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.
Authors:	Connolly, Stuart J Milling, Truman J Eikelboom, John W Gibson, C Michael Curnutte, John T Gold, Alex Bronson, Michele D Lu, Genmin Conley, Pamela B Verhamme, Peter Schmidt, Jeannot Middeldorp, Saskia Cohen, Alexander T Beyer-Westendorf, Jan Albaladejo, Pierre Lopez-Sendon, Jose Goodman, Shelly Leeds, Janet Wiens, Brian L Siegal, Deborah M Zotova, Elena Meeks, Brandi Nakamya, Juliet Lim, W Ting Crowther, Mark View more
Mesh:	Acute Disease Aged Aged, 80 and over Cardiovascular Diseases Enoxaparin Factor Xa Factor Xa Inhibitors Female Gastrointestinal Hemorrhage Hemorrhage Humans Infusions, Intravenous Intracranial Hemorrhages Male Prospective Studies Pyrazoles Pyridones Recombinant Proteins Rivaroxaban Thrombosis View more
Issue Date:	2016
Citation:	N. Engl. J. Med..2016 09;(375)12:1131-41
Abstract:	Andexanet alfa (andexanet) is a recombinant modified human factor Xa decoy protein that has been shown to reverse the inhibition of factor Xa in healthy volunteers.
PMID:	27573206
URI:	https://hdl.handle.net/20.500.12530/25415
Rights:	openAccess
Appears in Collections:	Fundaciones e Institutos de Investigación > IIS H. U. La Paz > Artículos

Files in This Item:

File	Description	Size	Format
PMC5568772.pdf		342.24 kB	Adobe PDF	View/Open